Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

F. Persson*, P. Rossing, H. Reinhard, T. Juhl, C.D.A. Stehouwer, C.G. Schalkwijk, A.H. Danser, F. Boomsma, E. Frandsen, H.H. Parving

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial'. Together they form a unique fingerprint.

Keyphrases

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences